Calcium Phosphate Nanoparticle (CaPNP) for Dose-Sparing of Inactivated Whole Virus Pandemic Influenza A (H1N1) 2009 Vaccine in Mice
Identifieur interne : 000737 ( Main/Exploration ); précédent : 000736; suivant : 000738Calcium Phosphate Nanoparticle (CaPNP) for Dose-Sparing of Inactivated Whole Virus Pandemic Influenza A (H1N1) 2009 Vaccine in Mice
Auteurs : Tülin Morç L [États-Unis] ; Brett L. Hurst [États-Unis] ; E. Bart Tarbet [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2017.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques, Animaux, Anticorps antiviraux (sang), Femelle, Grippe humaine (), Humains, Hydroxyde d'aluminium (immunologie), Immunoglobuline G (sang), Immunogénicité des vaccins, Infections à Orthomyxoviridae (), Nanoparticules (), Pandémies (), Phosphates de calcium (immunologie), Relation dose-réponse (immunologie), Souris, Sous-type H1N1 du virus de la grippe A (immunologie), Tests d'inhibition de l'hémagglutination, Tests de neutralisation, Utilisation hors indication, Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins inactivés (), Vaccins inactivés (administration et posologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Hydroxyde d'aluminium, Phosphates de calcium, Sous-type H1N1 du virus de la grippe A.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Adjuvants immunologiques, Animaux, Femelle, Grippe humaine, Humains, Immunogénicité des vaccins, Infections à Orthomyxoviridae, Nanoparticules, Pandémies, Relation dose-réponse (immunologie), Souris, Tests d'inhibition de l'hémagglutination, Tests de neutralisation, Utilisation hors indication, Vaccination, Vaccins inactivés.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Aluminum Hydroxide (immunology), Animals, Antibodies, Viral (blood), Calcium Phosphates (immunology), Dose-Response Relationship, Immunologic, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Immunoglobulin G (blood), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (prevention & control), Mice, Nanoparticles (chemistry), Neutralization Tests, Off-Label Use, Orthomyxoviridae Infections (prevention & control), Pandemics (prevention & control), Vaccination, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (chemistry).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , chemistry : Vaccines, Inactivated.
- chemical , immunology : Aluminum Hydroxide, Calcium Phosphates.
- chemical : Adjuvants, Immunologic.
- chemistry : Nanoparticles.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections, Pandemics.
- Animals, Dose-Response Relationship, Immunologic, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Mice, Neutralization Tests, Off-Label Use, Vaccination.
Abstract
The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical’s proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3 μg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3rd of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP’s capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.
Url:
DOI: 10.1016/j.vaccine.2017.07.016
PubMed: 28716554
PubMed Central: 5562532
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000867
- to stream Pmc, to step Curation: 000867
- to stream Pmc, to step Checkpoint: 000258
- to stream PubMed, to step Corpus: 000395
- to stream PubMed, to step Curation: 000395
- to stream PubMed, to step Checkpoint: 000430
- to stream Ncbi, to step Merge: 001C92
- to stream Ncbi, to step Curation: 001C92
- to stream Ncbi, to step Checkpoint: 001C92
- to stream Main, to step Merge: 000739
- to stream Main, to step Curation: 000737
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium Phosphate Nanoparticle (CaPNP) for Dose-Sparing of Inactivated Whole Virus Pandemic Influenza A (H1N1) 2009 Vaccine in Mice</title><author><name sortKey="Morc L, Tulin" sort="Morc L, Tulin" uniqKey="Morc L T" first="Tülin" last="Morç L">Tülin Morç L</name><affiliation wicri:level="2"><nlm:aff id="A1">CaPtivate Pharmaceuticals LLC, Doylestown, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>CaPtivate Pharmaceuticals LLC, Doylestown, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Hurst, Brett L" sort="Hurst, Brett L" uniqKey="Hurst B" first="Brett L." last="Hurst">Brett L. Hurst</name><affiliation wicri:level="2"><nlm:aff id="A2">Institute for Antiviral Research, Utah State University, Logon, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logon, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Tarbet, E Bart" sort="Tarbet, E Bart" uniqKey="Tarbet E" first="E. Bart" last="Tarbet">E. Bart Tarbet</name><affiliation wicri:level="2"><nlm:aff id="A2">Institute for Antiviral Research, Utah State University, Logon, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logon, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28716554</idno><idno type="pmc">5562532</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562532</idno><idno type="RBID">PMC:5562532</idno><idno type="doi">10.1016/j.vaccine.2017.07.016</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000867</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000867</idno><idno type="wicri:Area/Pmc/Curation">000867</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000867</idno><idno type="wicri:Area/Pmc/Checkpoint">000258</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000258</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:28716554</idno><idno type="wicri:Area/PubMed/Corpus">000395</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000395</idno><idno type="wicri:Area/PubMed/Curation">000395</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000395</idno><idno type="wicri:Area/PubMed/Checkpoint">000430</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000430</idno><idno type="wicri:Area/Ncbi/Merge">001C92</idno><idno type="wicri:Area/Ncbi/Curation">001C92</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C92</idno><idno type="wicri:doubleKey">0264-410X:2017:Morc L T:calcium:phosphate:nanoparticle</idno><idno type="wicri:Area/Main/Merge">000739</idno><idno type="wicri:Area/Main/Curation">000737</idno><idno type="wicri:Area/Main/Exploration">000737</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Calcium Phosphate Nanoparticle (CaPNP) for Dose-Sparing of Inactivated Whole Virus Pandemic Influenza A (H1N1) 2009 Vaccine in Mice</title><author><name sortKey="Morc L, Tulin" sort="Morc L, Tulin" uniqKey="Morc L T" first="Tülin" last="Morç L">Tülin Morç L</name><affiliation wicri:level="2"><nlm:aff id="A1">CaPtivate Pharmaceuticals LLC, Doylestown, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>CaPtivate Pharmaceuticals LLC, Doylestown, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Hurst, Brett L" sort="Hurst, Brett L" uniqKey="Hurst B" first="Brett L." last="Hurst">Brett L. Hurst</name><affiliation wicri:level="2"><nlm:aff id="A2">Institute for Antiviral Research, Utah State University, Logon, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logon, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Tarbet, E Bart" sort="Tarbet, E Bart" uniqKey="Tarbet E" first="E. Bart" last="Tarbet">E. Bart Tarbet</name><affiliation wicri:level="2"><nlm:aff id="A2">Institute for Antiviral Research, Utah State University, Logon, Utah, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Utah State University, Logon, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><idno type="eISSN">1873-2518</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Hydroxide (immunology)</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Calcium Phosphates (immunology)</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Immunoglobulin G (blood)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (prevention & control)</term><term>Mice</term><term>Nanoparticles (chemistry)</term><term>Neutralization Tests</term><term>Off-Label Use</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Pandemics (prevention & control)</term><term>Vaccination</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Hydroxyde d'aluminium (immunologie)</term><term>Immunoglobuline G (sang)</term><term>Immunogénicité des vaccins</term><term>Infections à Orthomyxoviridae ()</term><term>Nanoparticules ()</term><term>Pandémies ()</term><term>Phosphates de calcium (immunologie)</term><term>Relation dose-réponse (immunologie)</term><term>Souris</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Tests de neutralisation</term><term>Utilisation hors indication</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins inactivés ()</term><term>Vaccins inactivés (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Aluminum Hydroxide</term><term>Calcium Phosphates</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hydroxyde d'aluminium</term><term>Phosphates de calcium</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Mice</term><term>Neutralization Tests</term><term>Off-Label Use</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Animaux</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Infections à Orthomyxoviridae</term><term>Nanoparticules</term><term>Pandémies</term><term>Relation dose-réponse (immunologie)</term><term>Souris</term><term>Tests d'inhibition de l'hémagglutination</term><term>Tests de neutralisation</term><term>Utilisation hors indication</term><term>Vaccination</term><term>Vaccins inactivés</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical’s proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3 μg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3<sup>rd</sup> of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP’s capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.</p></div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li><li>Utah</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Morc L, Tulin" sort="Morc L, Tulin" uniqKey="Morc L T" first="Tülin" last="Morç L">Tülin Morç L</name></region><name sortKey="Hurst, Brett L" sort="Hurst, Brett L" uniqKey="Hurst B" first="Brett L." last="Hurst">Brett L. Hurst</name><name sortKey="Tarbet, E Bart" sort="Tarbet, E Bart" uniqKey="Tarbet E" first="E. Bart" last="Tarbet">E. Bart Tarbet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000737 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000737 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5562532
|texte= Calcium Phosphate Nanoparticle (CaPNP) for Dose-Sparing of Inactivated Whole Virus Pandemic Influenza A (H1N1) 2009 Vaccine in Mice
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28716554" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |